Evaluation of effectiveness of the ABLE 2.0 in a randomised controlled trial

  • Hagelskjær, V. (Oplægsholder)
  • Cecilie von Bülow (Oplægsholder)
  • Kristina Tomra Nielsen (Oplægsholder)
  • Eva Ejlersen Wæhrens (Oplægsholder)

Aktivitet: Tale, præsentation eller oplæg f.eks. på konferencer og til praksisForedrag eller oplæg

Beskrivelse

ABSTRACT:
Background: ABLE 2.0 was developed aiming to enhance activities of daily living (ADL) ability among people with chronic conditions (1). It is a complex occupational therapy intervention, using occupation-focused/occupation-based approaches (2), in a five-to-eight-week homebased adaptational program. Feasibility and pilot studies were conducted (3,4).
Objectives: Compare effectiveness of ABLE 2.0 to usual occupational therapy (UOT), on ADL ability in people with chronic conditions.
Methods: A double-blinded, randomised controlled trial with 10- and 26-week follow-up in a Danish municipality. Participants were randomly assigned to ABLE 2.0 or UOT. Co-primary outcomes were self-reported ADL ability (ADL-Interview (ADL-I) performance) and observed ADL motor ability (Assessment of Motor and Process Skills (AMPS)).
Results: 78 persons were randomly assigned to ABLE 2.0 or UOT. No statistically significant nor clinically relevant difference between group mean changes in primary outcomes was identified at Week 10 (ADL-I Performance [−0.16; 95% CI: −0.38 to 0.06] and AMPS ADL motor ability [−0.1; 95% CI: −0.3 to 0.1]). At Week 26, a statistically significant and clinically relevant difference was found in AMPS ADL motor ability (LS mean change: −0.3; 95% CI: −0.5 to −0.1) between groups (5).
Conclusion: ABLE 2.0 was effective in improving observed ADL motor ability at 26 weeks.

Periode15 okt. 2024
BegivenhedstitelOT-Europe Congress 2024
BegivenhedstypeKonference
PlaceringKrakow, PolenVis på kort